Remove 2017 Remove Immune Response Remove Research
article thumbnail

Leveraging agonist antibodies to address immunological diseases

Drug Target Review

Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors. In these conditions, the goal of therapy is typically to suppress or mitigate immune activity.

Disease 52
article thumbnail

Cancer immunotherapy candidate provokes powerful dual response in cancer and immune cells

Broad Institute

Researchers from the Tumor Immunotherapy Discovery Engine ( TIDE ) at the Broad Institute of MIT and Harvard, AbbVie, and Calico Life Sciences report that the molecule simultaneously makes tumors more sensitive to immune attack and boosts the activity of immune cells to fight tumors in mice.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

#WhyIScience Q&A: A microbiologist and immunologist finds links between our own microbes and disease mechanisms

Broad Institute

After completing his PhD in 2017, Brown joined Xavier’s lab as a postdoctoral researcher and has been at the Broad ever since, now as a staff scientist. We spoke with Brown about his experience as both a researcher and a patient in this #WhyIScience Q&A. What keeps you motivated to keep doing research?

Disease 125
article thumbnail

CAR-NK cells: promising for cancer therapy

Drug Target Review

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118
article thumbnail

Merck Strikes $1B+ Deal to Leverage Janux’s T Cell Engager Program Against Cancer

The Pharma Data

In preclinical studies, Janux TRACTr drug candidates have demonstrated comparable anti-tumor efficacy relative to standard T cell engagers but lack the associated liabilities related to cytokine release, healthy tissue toxicities, or systemic immune activation, the company said. “At Janux, in exchange, will receive up to $500.5

article thumbnail

Laurie Glimcher

Broad Institute

Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research. Beering Award for outstanding research contributions to advancement of biomedical or clinical science; and the L'Oréal-UNESCO Award for Women in Science. She has also received the 2017 George M.

article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers. Mr Ho has worked in the biotechnology industry for almost 20 years.

Therapies 105